Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amzeeq
- Development stage
- Approved
- Lead developer
- Foamix Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Amzeeq is a topical foam formulation of minocycline, a tetracycline-class antibiotic. It is used to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Minocycline works by inhibiting bacterial protein synthesis, which helps reduce acne-causing bacteria on the skin. Amzeeq is applied once daily, at least one hour before bedtime, and should not be used in the mouth, eyes, or vagina. It is the first topical formulation of minocycline approved by the FDA for any condition.
- Brand names
- Amzeeq
- Other names
- Minocycline topical foam
02
Targets
Bacterial RibosomeNeuraminidase
Beyond the preview
Go deeper on Amzeeq.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amzeeq.